The U.S. Supreme Court agreed to hear Hikma v. Amarin to answer a narrow question. It may end up saying far more about how policymakers misunderstand pharmaceutical markets.
On its face, the case is narrow. It asks whether a generic drug manufacturer can face liability for inducing patent infringement based on how it markets a product approved under a so-called “skinny label.” The dispute turns on whether Hikma’s conduct plausibly encouraged physicians to prescribe its generic drug for a patented use.
But the Court’s decision to grant certiorari hints at something broader. It reflects a persistent belief that regulators and courts can engineer complex pharmaceutical markets to deliver lower prices—chiefly by speeding generic entry.
That belief misses the mark. Worse, it risks undermining the innovation that produces new therapies in the first place.
Hatch-Waxman’s Strategic Reality
Since 1984, U.S. drug policy has been shaped by the Hatch-Waxman Act—a statute meant to balance innovation and competition. The premise was simple: allow generics to enter quickly after patent expiration to drive down prices, while granting additional patent terms and data exclusivities to preserve incentives for innovation.
That balance has proved elusive.
Instead of a streamlined path to competition, Hatch-Waxman has produced a dense, highly strategic legal environment. Brand manufacturers engage in lifecycle management, including building portfolios of follow-on patents. Generic firms exploit regulatory mechanisms such as the 180-day market exclusivity period. Both sides lean heavily on litigation and settlement strategies—most notably so-called “pay-for-delay” agreements—to shape when products reach the market.
The result is not a tidy story about delayed competition. It is a complex, litigation-heavy ecosystem that often looks nothing like what Congress envisioned.
Many observers call this a policy failure. A better reading sees something more basic: the predictable outcome of trying to design, ex ante, the optimal structure of a dynamic, uncertain market.
The Fatal Conceit, Now in Pill Form
Economist Friedrich A. Hayek warned against what he called the “fatal conceit”—the belief that policymakers can design complex social systems that depend on knowledge they do not possess.
Pharmaceutical innovation is exactly that kind of system.
Drug development is uncertain, decentralized, and constantly adapting. Firms invest billions without knowing which research paths will succeed, which therapies will prove effective, or how future discoveries will reshape the competitive landscape. Some of the most valuable advances—including new uses for existing drugs—emerge only after years of follow-on research.
No legislature can see that far ahead. No statute can pre-calibrate the right balance between innovation and competition.
Yet Hatch-Waxman tries to do just that.
The statute assumes Congress can specify when generic entry should occur and how much protection innovators need to sustain investment. In a system defined by dispersed, evolving knowledge, that assumption collapses. Firms adapt. They arbitrage incentives. Legal rules become just another input into strategic behavior.
The rise of so-called “patent thickets,” pay-for-delay settlements, and prolonged litigation timelines are not aberrations. They are the predictable result of imposing a designed framework on a system that resists design.
Skinny Labels, Fat Problems
Hikma v. Amarin makes sense only against this backdrop.
Amarin’s drug, Vascepa, was first approved for a narrow use. The company later invested heavily to identify a new cardiovascular indication—one that significantly reduces the risk of heart attack and stroke. That second use, now the drug’s primary clinical value, reflects exactly the kind of post-approval innovation the patent system is meant to reward.
Hikma plans to market a generic version using a “skinny label” that omits the patented indication. Amarin argues that Hikma’s broader communications and marketing still encourage physicians to prescribe the drug for that protected use.
The legal question is whether that conduct can support liability for induced infringement.
Petitioners ask the Court to adopt a more rigid rule—one that would effectively shield generic manufacturers from liability so long as their labeling formally excludes the patented use.
That rule may look clean on paper. But it repeats the same mistake embedded in Hatch-Waxman: the idea that formal legal categories can stand in for context-specific analysis of real-world behavior.
Inducement doctrine does not work that way. It is inherently fact-driven. It asks what firms actually do—not just what they say in regulatory filings. Replace that inquiry with a bright-line safe harbor, and the system does not get simpler. It gets distorted.
You Can’t Generic Your Way to Innovation
At bottom, Hikma rests on a familiar policy instinct: faster generic entry is the main fix for high drug prices.
That instinct is incomplete.
Generic competition lowers prices—but only after innovation has done its work. It does not produce the next generation of therapies. Weaken the mechanisms that let innovators capture the value of their discoveries, and you risk cutting the investment that makes future competition possible.
A more durable path to lower prices runs through innovation, not just generics. It means more drugs competing within therapeutic classes—and entirely new classes that reshape treatment options.
That kind of competition expands patient choice and puts downward pressure on prices over time.
But it depends on a legal framework that reliably protects returns to risky, uncertain research—especially in areas like post-approval innovation, where the benefits often emerge only after initial approval.
The Court Passes on the Real Issue
If the Supreme Court wants to address the structural drivers of pharmaceutical innovation, it does not have to look far.
For years, litigants have asked the Court to clarify its fractured, unpredictable patent subject matter eligibility (SME) doctrine under § 101. Those petitions go to the core of the innovation economy.
The Court has repeatedly declined to take them.
That choice carries consequences. SME doctrine now creates acute uncertainty for diagnostic technologies—an area central to modern medicine. Many cutting-edge therapies, especially in oncology, rely on companion diagnostics to identify which patients will benefit. When patent protection for those diagnostics is unclear or unavailable, investment predictably falls.
Clarifying—and where appropriate, expanding—patent eligibility would do far more to promote innovation, and ultimately competition, than continued tinkering with the timing of generic entry.
Instead, the Court has opted to focus on a narrow dispute over induced infringement under Hatch-Waxman.
The Blueprint Fallacy
The deeper problem is not doctrinal. It is conceptual.
Efforts to manage drug pricing through ever more intricate legal and regulatory schemes reflect an overconfidence in policymakers’ ability to design outcomes in systems they cannot fully understand. The premise is that the right mix of rules can deliver both lower prices and optimal innovation.
Hayek warned against that kind of confidence.
Markets are not machines to be engineered. They are discovery processes, shaped by dispersed knowledge and constant adaptation. Legal frameworks can support those processes. They cannot substitute for them.
Hatch-Waxman—and the policy mindset behind it—tries to do exactly that.
A Missed Opportunity
The Supreme Court’s docket is limited. Every case it takes signals what it thinks matters.
By choosing Hikma v. Amarin, the Court has opted to address a narrow question that tracks prevailing concerns about drug pricing—while leaving unresolved deeper uncertainties in patent law that shape innovation across the entire economy.
That choice is revealing.
The real problem is not that generics enter too slowly. It is that the legal framework governing innovation has grown unstable, complex, and increasingly detached from how innovation actually happens.
Fixing that problem will take more than incremental doctrinal tweaks. It requires recognizing the limits of centralized design—and recommitting to the principles that let decentralized innovation work.
